Regaal Resources Q1 FY27: Lower Revenue, Higher Profitability, and a Big Capacity Ramp Ahead

Regaal Resources opened FY27 with a quarter that looks counterintuitive on the surface. Revenue from operations in Q1 FY27 came in at INR 202.15 crore, down 18% year-on-year. But operating profitability improved sharply. Operating EBITDA rose 26.6% year-on-year to INR 30.98 crore and profit after tax grew 47% to INR 13.33 crore.

The bridge between lower revenue and higher profit was mix. Management described a deliberate reduction in low-margin trading activity, shifting the quarter toward manufacturing-led revenue. Trading contribution reduced to 3.3% in Q1 FY27 from 19.5% in Q1 FY26. That decision pushed up value-add, which the company defines as operating income minus cost of goods sold. Value-add in Q1 FY27 increased to INR 80.53 crore and value-add margin expanded to 39.8% from 25.1% a year ago.

Another reason this quarter matters is timing. Regaal commissioned a major capacity expansion on 26 May 2026, doubling maize crushing capacity from 825 TPD to 1,650 TPD. It also commissioned a Liquid Glucose facility of 180 TPD, a Maltodextrin Powder facility of 50 TPD and expanded its captive co-generation power plant from 7.1 MW to 15.8 MW. Management described Q1 FY27 as a transition quarter because the expanded plant started operations only in early June and required integration-related shutdown days during April and May.

Profitability improved even as operating income declined

The quarter’s headline numbers show a clear improvement in profitability ratios. Operating EBITDA margin expanded to 15.3% in Q1 FY27 from 9.9% in Q1 FY26. PAT margin increased to 6.6% from 3.7%. Management attributed the improvement largely to operating leverage and the reduced contribution of trading.

The company also highlighted a growing international footprint. Export contribution increased to 10.4% in Q1 FY27 compared with 4.9% in Q1 FY26. The investor deck also provides an export sales figure of INR 20.77 crore for Q1 FY27.

Table: Financial snapshot

Capacity expansion: the commissioning is done, the ramp-up is next

The expansion commissioned on 26 May 2026 is central to the FY27 narrative. Management said the newly commissioned capacities were in stabilization and ramp-up during Q1 FY27, and benefits are expected to start reflecting from Q2 FY27 onwards.

Utilization in Q1 FY27 was reported at 71.4%, which management linked to commissioning and integration. On the call, management also stated there were around nine shutdown days during April and May for integration, and this affected production.

Operationally, maize crushing production increased to 69,689 metric tons in Q1 FY27 from 64,770 metric tons in Q1 FY26, a growth of 7.6%. Management gave an indication for the year, stating it expects FY27 crushing volumes to go above 400,000 tons.

The company’s near-term product ramp is tilted toward derivatives. Management stated that the incremental Q1 volume was largely utilized for liquid glucose and only a small part for maltodextrin powder. It also noted that maltodextrin typically requires longer customer qualification cycles and indicated it could take two to three months to reach targeted levels.

Mix shift and product strategy: value-added is the goal, but timing matters

In Q1 FY27, the company’s revenue mix was still dominated by native maize starch. As per the investor presentation’s segment mix chart for Q1 FY27, native maize starch accounted for 61.7% of revenue, modified starch 31.1%, co-products 3.2%, value-added products 3.3% and trading and others 0.7%.

Management’s commentary suggests this is expected to change as derivative capacities stabilize. On the call, management said value-added products were about 3% of turnover last year and it expects that to rise to 20% to 22% of turnover in FY27. It also discussed a broader product pipeline, including planned entry into Dextrose Anhydrous, Dextrose Monohydrate and Hydrol. While the investor deck mentions commissioning planned in phases through FY27, management added on the call that dextrose could be visible by the fourth quarter before March.

The company also described its go-to-market approach for new modified starch products, indicating that a large portion of new products can be sold through existing dealer and institutional channels, with cross-selling into industries such as paper and food.

Balance sheet and working capital: the cost of scaling

A ramp-up quarter is rarely clean on working capital, and Regaal’s numbers reflect that. Cash conversion cycle increased to 130 days in Q1 FY27 versus 50 days in FY26, driven by annualized inventory days of 208. The annexure explains this as a result of higher inventory built to support the expanded 1,650 TPD capacity, while revenue contribution from the new capacity had not yet fully flowed through during the quarter.

Net debt also increased to INR 735.32 crore as of 30 June 2026. Leverage metrics worsened on an annualized basis, with Net Debt to Operating EBITDA at 5.9x in Q1 FY27. Management described this as linked to the expansion program and seasonal raw material procurement. It also stated that debt raised for the new capex qualifies for interest subvention under Bihar’s industrial policy, reducing effective cost of borrowing.

On the concall, the CFO provided a numerical expectation for FY27 net interest cost, stating it should be around INR 39 to 40 crore net of subvention. Management also indicated that working capital and debt tend to peak in the first half and reduce in the second half as the procurement cycle normalizes.

Takeaways

Regaal’s Q1 FY27 is best read as the first quarter after a large commissioning event rather than a steady-state performance quarter. Revenue fell due to a deliberate reduction in trading, but margins expanded because manufacturing-led value-add improved. The bigger question for the next few quarters is execution on the ramp-up: higher utilization, scaling new derivative lines like liquid glucose and maltodextrin, and translating the expanded asset base into better cash generation.

For investors, the key watch points remain utilization progress from Q2 FY27, the pace at which value-added mix rises toward management’s stated expectations, and whether working capital normalizes as production scales. The company has indicated it is moving from a capex-led phase to a cash generation and deleveraging phase. Whether that transition plays out cleanly will define the FY27 narrative.